Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.
PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, S-171 76 Stockholm, Sweden.
ACS Chem Neurosci. 2023 Oct 18;14(20):3732-3736. doi: 10.1021/acschemneuro.3c00458. Epub 2023 Sep 27.
Undesired radiometabolites can be detrimental to the development of positron emission tomography (PET) radioligands. Methods for quantifying radioligand metabolites in brain tissue include ex vivo studies in small animals or labeling and imaging of the radiometabolite(s) of interest. The latter is a time- and resource-demanding process, which often includes multistep organic synthesis. We hypothesized that this process could be replaced by making use of liver microsomes, an in vitro system that mimics metabolism. In this study, rat liver microsomes were used to prepare radiometabolites of the dopamine transporter radioligand [F]FE-PE2I for in vitro imaging using autoradiography and in vivo imaging using PET in rats and nonhuman primates. The primary investigated hydroxy-metabolite [F]FE-PE2I-OH ([F]) was obtained in a 2% radiochemical yield and >99% radiochemical purity. In vitro and in vivo imaging demonstrated that [F] readily crossed the blood-brain barrier and bound specifically and reversibly to the dopamine transporter. In conclusions, the current study demonstrates the potential of liver microsomes in the production of radiometabolites for translational imaging studies and radioligand discovery.
未代谢的放射性代谢物可能会对正电子发射断层扫描(PET)放射性配体的发展产生不利影响。定量检测脑组织中放射性配体代谢物的方法包括小动物的离体研究或感兴趣的放射性代谢物的标记和成像。后者是一个耗时且资源密集型的过程,通常包括多步有机合成。我们假设可以利用肝脏微粒体(一种模拟代谢的体外系统)来替代这个过程。在这项研究中,使用大鼠肝脏微粒体来制备多巴胺转运体放射性配体[F]FE-PE2I 的放射性代谢物,用于使用放射自显影进行体外成像和使用 PET 在大鼠和非人类灵长类动物进行体内成像。主要研究的羟基代谢物[F]FE-PE2I-OH([F])的放射性化学产率为 2%,放射性化学纯度>99%。体外和体内成像研究表明,[F]很容易穿过血脑屏障,并特异性和可逆地与多巴胺转运体结合。总之,目前的研究表明肝脏微粒体在生产放射性代谢物用于转化成像研究和放射性配体发现方面具有潜力。